This study is based on estimation of a biomarker named Nt pro BNP produced by the cardiac cells in preterm newborns having a heart defect called patent ductus arteriosus.
Not Applicable
- Conditions
- Health Condition 1: Q250- Patent ductus arteriosus
- Registration Number
- CTRI/2023/04/051604
- Lead Sponsor
- Dr Abhoorvaa OC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All Preterm infants born before 36 weeks of gestation admitted in NICU undergoing echocardiography evaluation
Exclusion Criteria
Other congenital heart diseases
Neonatal Sepsis
Bronchopulmonary dysplasia
Congenital anomalies/malformations
Blleding tendency
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Estimation of NT-pro BNP in preterm newborn with PDATimepoint: At baseline
- Secondary Outcome Measures
Name Time Method To correlate the levels of NT-pro BNP with hemodynamically significant PDA in preterm newbornsTimepoint: 1 week